Lorin Graef, MD
Neurology · Boca Raton, FLNPI 1750343703
Payments from drug & device makers
Across 167 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$523
- Eisai Inc.$419
- Argenx US, Inc.$352
- MDD US Operations, LLC$261
- Otsuka America Pharmaceutical, Inc.$260
- plus $970 from 18 others
What the payments were for
- Food & beverage$4,346100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,568 |
| Lilly USA, LLC | 18 | $523 |
| Eisai Inc. | 10 | $419 |
| Argenx US, Inc. | 13 | $352 |
| MDD US Operations, LLC | 5 | $261 |
| Otsuka America Pharmaceutical, Inc. | 7 | $260 |
| Merz Pharmaceuticals, LLC | 7 | $161 |
| Biohaven Pharmaceuticals, Inc. | 4 | $157 |
| Biogen | 6 | $122 |
| Pfizer | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| AstraZeneca | 2 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Novartis | 2 | $32 |
| Lundbeck LLC | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Brainsway USA Inc | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Insightec,inc | 1 | $21 |
| Cala Health, Inc. | 1 | $21 |
| Revance Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,353 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 809 | $28,976 |
| Duloxetine Hcl | 751 | $17,943 |
| Emgality PenGalcanezumab-Gnlm | 14 | $13,857 |
| Gabapentin | 549 | $8,512 |
| Rivastigmine | 29 | $7,479 |
| Escitalopram Oxalate | 481 | $7,469 |
| Galantamine ErGalantamine Hbr | 65 | $6,567 |
| Donepezil Hcl | 445 | $6,196 |
| Pregabalin | 150 | $5,110 |
| Entacapone | 37 | $3,932 |
| Memantine Hcl ErMemantine Hcl | 33 | $3,125 |
| Primidone | 105 | $2,861 |
| Levetiracetam | 55 | $2,767 |
| Bupropion XlBupropion Hcl | 78 | $2,535 |
| Buspirone Hcl | 146 | $2,473 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boca Raton
- Stuart IsaacsonBoca Raton$10.5M
- Brian SteingoBoca Raton$4.6M
- Marc FeinbergBoca Raton$3.2M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.